EVMN — Evommune, Inc.
Price · 2025-11-06 → 2026-08-21
198 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2025-11-06.
Performance
Technicals
Others in Healthcare
Measured signals that fired on EVMN
| date | signal | measured base rate |
|---|---|---|
| 2026-08-05 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-02 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-06-29 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-29 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-06-08 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-04-09 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-08 | Carver Kyle Chief Financial Officer | Open-market purchase | 1.0K | 13.26 | 13.3K |
| 2026-07-07 | KIRSCH ARTHUR S Director | Open-market purchase | 10.0K | 13.30 | 133.0K |
| 2026-06-22 | Drew Janice Suzann Chief of Dev. Operations | Open-market sale 10b5-1 plan | 20.0K | 22.63 | 452.6K |
| 2026-06-22 | Pena Luis C. President & CEO | Open-market sale 10b5-1 plan | 7.4K | 22.71 | 168.9K |
| 2026-06-22 | Drew Janice Suzann Chief of Dev. Operations | Option exercise 10b5-1 plan | 16.2K | 2.99 | 48.3K |
| 2026-06-22 | Patel Jeegar Pravinkumar Chief Scientific Officer | Open-market sale 10b5-1 plan | 1.5K | 22.50 | 33.5K |
| 2026-06-22 | Drew Janice Suzann Chief of Dev. Operations | Option exercise 10b5-1 plan | 3.8K | 3.84 | 14.7K |
| 2026-06-22 | Patel Jeegar Pravinkumar Chief Scientific Officer | Option exercise 10b5-1 plan | 1.5K | 3.84 | 5.7K |
| 2026-06-02 | Cohen David E Director | Open-market sale 10b5-1 plan | 5.5K | 20.21 | 110.3K |
| 2026-06-02 | Cohen David E Director | Open-market sale 10b5-1 plan | 600 | 21.38 | 12.8K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| EQT Fund Management S.a r.l. | 113.3M | 4.9M |
| RA CAPITAL MANAGEMENT, L.P. | 80.3M | 3.5M |
| Pivotal bioVenture Partners Investment Advisor LLC | 44.3M | 1.9M |
| ANDERA PARTNERS | 43.6M | 1.9M |
| RTW INVESTMENTS, LP | 34.5M | 1.5M |
| MPM BIOIMPACT LLC | 33.5M | 1.5M |
| Nan Fung Group Holdings Ltd | 33.1M | 1.4M |
| JPMORGAN CHASE & CO | 32.1M | 1.5M |
| SymBiosis Capital Partners, LLC | 29.4M | 1.3M |
| EVENTIDE ASSET MANAGEMENT, LLC | 27.8M | 1.2M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| 424B3 | 2026-08-06 | — | on EDGAR ↗ |
| 10-Q | 2026-08-06 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-06 | 2026-08-06 | on EDGAR ↗ |
| 8-K | 2026-07-30 | 2026-07-29 | on EDGAR ↗ |
| SCHEDULE 13G | 2026-07-16 | — | on EDGAR ↗ |
| 4 | 2026-07-10 | 2026-07-08 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Evommune, Inc. (EVMN) filed form SCHEDULE 13G · 2026-08-14 · SEC EDGAR
- Evommune, Inc. (EVMN) filed form SCHEDULE 13G/A · 2026-08-14 · SEC EDGAR
Ask the AI about EVMN
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →